全文获取类型
收费全文 | 2346篇 |
免费 | 89篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 86篇 |
妇产科学 | 102篇 |
基础医学 | 168篇 |
口腔科学 | 58篇 |
临床医学 | 368篇 |
内科学 | 560篇 |
皮肤病学 | 97篇 |
神经病学 | 129篇 |
特种医学 | 33篇 |
外科学 | 325篇 |
综合类 | 96篇 |
一般理论 | 10篇 |
预防医学 | 161篇 |
眼科学 | 22篇 |
药学 | 161篇 |
肿瘤学 | 33篇 |
出版年
2016年 | 9篇 |
2015年 | 26篇 |
2014年 | 30篇 |
2013年 | 36篇 |
2012年 | 13篇 |
2011年 | 10篇 |
2010年 | 56篇 |
2009年 | 64篇 |
2008年 | 9篇 |
2007年 | 12篇 |
2005年 | 9篇 |
2003年 | 14篇 |
2001年 | 20篇 |
2000年 | 14篇 |
1999年 | 35篇 |
1998年 | 40篇 |
1997年 | 86篇 |
1996年 | 65篇 |
1995年 | 44篇 |
1994年 | 62篇 |
1993年 | 48篇 |
1992年 | 45篇 |
1991年 | 41篇 |
1990年 | 48篇 |
1989年 | 32篇 |
1988年 | 47篇 |
1987年 | 35篇 |
1986年 | 29篇 |
1985年 | 16篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 29篇 |
1981年 | 25篇 |
1980年 | 23篇 |
1979年 | 27篇 |
1978年 | 14篇 |
1977年 | 22篇 |
1976年 | 20篇 |
1975年 | 13篇 |
1972年 | 9篇 |
1971年 | 9篇 |
1963年 | 14篇 |
1959年 | 94篇 |
1958年 | 166篇 |
1957年 | 173篇 |
1956年 | 179篇 |
1955年 | 159篇 |
1954年 | 184篇 |
1949年 | 48篇 |
1948年 | 55篇 |
排序方式: 共有2435条查询结果,搜索用时 15 毫秒
1.
JANE P. F. BAI HAE-JIN HONG DAVID A. ROTH ENBERGER W. DOUGLAS WONG JOHN G. BULS 《The Journal of pharmacy and pharmacology》1996,48(11):1180-1184
The aim of this research is to characterize the presence of insulin-degrading enzyme in human colon and ileal mucosal cells. Biochemical studies, including the activity-pH profiles, the effects of enzyme inhibitors, immunoprecipitation and western blots, were conducted. The majority of insulin-degrading activity in colon mucosal cells was localized in the cytosol. In both colon and ileum, cytosolic insulin-degrading activities had a pH optimum at pH 7.5, and were extensively inhibited by each of N-ethylmaleimide, p-chloromercuribenzoate, and 1,10-phenanthroline, but were very weakly affected by each of leupeptin, chymostatin, diisopropyl phosphofluoridate and soybean trypsin inhibitor. In the colon and ileum, more than 93% and 96%, respectively, of cytosolic insulin-degrading activities were removed by the mouse monoclonal antibody to human RBC insulin-degrading enzyme, as compared with less than 20% by the normal mouse IgG for both tissues. Further, a western blot analysis revealed that a cytosolic protein of 110 kD, in both human colon and ileum, reacted with the monoclonal antibody to insulin-degrading enzyme. It is concluded that insulin-degrading enzyme is present in the cytosol of human colon and ileal mucosal cells. 相似文献
2.
LI-FERN HSU PIERRE JAÏS MÉLÈZE HOCINI PRASHANTHAN SANDERS MARTIN ROTTER YOSHIHIDE TAKAHASHI CHRISTOPHE SCAVÉE FREDERIC SACHER JACQUES CLÉMENTY MICHEL HAÏSSAGUERRE 《Pacing and clinical electrophysiology : PACE》2005,28(S1):S94-S98
The differentiation of pulmonary vein (PV) electrograms from atrial far-field signals during PV isolation (PVI) for atrial fibrillation (AF) may be difficult. In addition, owing to highly variable PV ostial sizes, current fixed-diameter circular PV mapping catheters may not yield optimal electrograms. We evaluated an expandable, circular 15–25 mm diameter, 20-pole mapping catheter for PV mapping during sustained AF in 25 patients. After selective PV angiography to define the ostial position and size, the catheter was introduced into each PV and withdrawn to the most stable proximal position, with optimal wall contact ensured by progressive loop expansion. At each PV ostium, electrograms recorded at high resolution (HR) were compared with those recorded at a resolution similar to that of a standard 10-pole Lasso catheter. After PVI performed during ongoing AF, the presence of residual far-field potentials (FFP) under both set-ups was compared. We mapped 97 PV, including 4 pairs with common ostia. In the HR recordings, the PV potentials had greater amplitude (0.5 ± 0.1 vs 0.3 ± 0.1 mV, P = 0.001) and fragmentation, whereas left atrial FFP were minimized. After successful isolation of all PV, FFP were observed in 33% of left superior and 28% of left inferior PV on the HR recordings, compared to 66% and 61%, respectively under normal resolution. Catheter stability and optimal wall contact, in combination with HR electrograms can optimize circumferential PV mapping during AF and improve the discrimination of FFP postablation. 相似文献
3.
Reliable discrimination between sinus tachycardia (ST) and pathologic tachycardia has been a major problem for automatic implantable antitachycardia devices. In patients whose sinus response to activity is as rapid or faster than their pathologic tachycardia (rate crossover), these unsophisticated devices deliver the programmed tachycardia response to either the pathologic or sinus tachycardia. Over a one-year period, 50 Intermedics Intertach Model 262–12 antitachycardia pulse generators were implanted to evaluate the specificity of a new group of tachycardia recognition algorithms. Patients were subjected to exercise testing and noninvasive programmed stimulation to demonstrate the efficacy of this new approach. The five recognition algorithms tested were various combinations of the following criteria: high rate HR), sudden onset (SO), rate stability (RS), and sustained high rate (SHR). False positive rates (tachycardia response inappropriately triggered by ST) were as follows: HR (93%); HR + SO (3%); HR + RS (63%); HR + (RS or SHR) (87%); HR + HS + SO (8%). Pair-wise significance testing between HR only and HR + SO (p < 0.001), HR + RS (p = 0.01) and HR + SO + RS (p < 0.001), demonstrated a significant reduction in the rate of false positives through the use of the sudden onset and rate stability criteria in concert with the standard high rate criterion. 相似文献
4.
5.
6.
7.
8.
9.
10.
BERNHARD FREY MICHAEL WUTTE RUDOLF BERGER CLEANTHIS IOANNIDES MARTIN HÜLSMANN BRIGITTE STANEK RICHARD PACKER 《Pacing and clinical electrophysiology : PACE》1995,18(1):152-158
To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease/dilated cardiomyopathy in 61/175 patients, left ventricular ejection fraction 14%± 5%, New York Heart Association Class IIl/IIIIV in 102/79/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirtyseven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninetynine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PGE1 for preand afterload reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 ± 9 months; patients who underwent staged therapy for 9 ±5 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died: 13 (52%) deaths occurred suddenly, and 12 (48%) deaths occurred due to progressive pump failure. Thus, patients who underwent staged therapy were at increased risk for sudden death (P = 0.01, relative risk 3.4, 95% confidence interval 1.2–9.7) but were at lower risk for death from pump failure (P = 0.009, relative risk 0.44, 95% confidence interval 0.22–0.84). In patients who underwent therapy with continuous outpatient PGE1 (n = 7) or dobutamine (n= 21), risk for sudden death (P = NS by log rank test) did not increase. In conclusion, staged therapy significantly reduced death from pump failure; however, patients who could be stabilized and considered too well for heart transplantation were at increased risk for sudden death. Thus, overall survival did not improve. Of note, outpatient dobutamine did not increase the risk for sudden death. 相似文献